14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Uncovering mutation-specific morphogenic phenotypes and paracrine-mediated vessel dysfunction in a biomimetic vascularized mammary duct platform

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The mammary gland is a highly vascularized tissue capable of expansion and regression during development and disease. To enable mechanistic insight into the coordinated morphogenic crosstalk between the epithelium and vasculature, we introduce a 3D microfluidic platform that juxtaposes a human mammary duct in proximity to a perfused endothelial vessel. Both compartments recapitulate stable architectural features of native tissue and the ability to undergo distinct forms of branching morphogenesis. Modeling HER2/ERBB2 amplification or activating PIK3CA( H1047R) mutation each produces ductal changes observed in invasive progression, yet with striking morphogenic and behavioral differences. Interestingly, PI3Kα H1047R ducts also elicit increased permeability and structural disorganization of the endothelium, and we identify the distinct secretion of IL-6 as the paracrine cause of PI3Kα H1047R-associated vascular dysfunction. These results demonstrate the functionality of a model system that facilitates the dissection of 3D morphogenic behaviors and bidirectional signaling between mammary epithelium and endothelium during homeostasis and pathogenesis.

          Abstract

          In vitro models of the human mammary gland have struggled to mimic the 3D morphogenic processes that occur in vivo. Here the authors develop a 3D microfluidic platform of a vascularized human mammary duct that simulates diverse morphogenic transitions and paracrine crosstalk.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: not found

          Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

          For almost four decades, my work has focused on one challenge: improving the delivery and efficacy of anticancer therapeutics. Working on the hypothesis that the abnormal tumor microenvironment-characterized by hypoxia and high interstitial fluid pressure--fuels tumor progression and treatment resistance, we developed an array of sophisticated imaging technologies and animal models as well as mathematic models to unravel the complex biology of tumors. Using these tools, we demonstrated that the blood and lymphatic vasculature, fibroblasts, immune cells, and extracellular matrix associated with tumors are abnormal, which together create a hostile tumor microenvironment. We next hypothesized that agents that induce normalization of the microenvironment can improve treatment outcome. Indeed, we demonstrated that judicious use of antiangiogenic agents--originally designed to starve tumors--could transiently normalize tumor vasculature, alleviate hypoxia, increase delivery of drugs and antitumor immune cells, and improve the outcome of various therapies. Our trials of antiangiogenics in patients with newly diagnosed and recurrent glioblastoma supported this concept. They revealed that patients whose tumor blood perfusion increased in response to cediranib survived 6 to 9 months longer than those whose blood perfusion did not increase. The normalization hypothesis also opened doors to treating various nonmalignant diseases characterized by abnormal vasculature, such as neurofibromatosis type 2. More recently, we discovered that antifibrosis drugs capable of normalizing the tumor microenvironment can improve the delivery and efficacy of nano- and molecular medicines. Our current efforts are directed at identifying predictive biomarkers and more-effective strategies to normalize the tumor microenvironment for enhancing anticancer therapies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Modelling cancer in microfluidic human organs-on-chips

            One of the problems that has slowed the development and approval of new anticancer therapies is the lack of preclinical models that can be used to identify key molecular, cellular and biophysical features of human cancer progression. This is because most in vitro cancer models fail to faithfully recapitulate the local tissue and organ microenvironment in which tumours form, which substantially contributes to the complex pathophysiology of the disease. More complex in vitro cancer models have been developed, including transwell cell cultures, spheroids and organoids grown within flexible extracellular matrix gels, which better mimic normal and cancerous tissue development than cells maintained on conventional 2D substrates. But these models still lack the tissue-tissue interfaces, organ-level structures, fluid flows and mechanical cues that cells experience within living organs, and furthermore, it is difficult to collect samples from the different tissue microcompartments. In this Review, we outline how recent developments in microfluidic cell culture technology have led to the generation of human organs-on-chips (also known as organ chips) that are now being used to model cancer cell behaviour within human-relevant tissue and organ microenvironments in vitro. Organ chips enable experimentalists to vary local cellular, molecular, chemical and biophysical parameters in a controlled manner, both individually and in precise combinations, while analysing how they contribute to human cancer formation and progression and responses to therapy. We also discuss the challenges that must be overcome to ensure that organ chip models meet the needs of cancer researchers, drug developers and clinicians interested in personalized medicine.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Organoids-on-a-chip

              Recent studies have demonstrated an array of stem cell–derived, self-organizing miniature organs, termed organoids, that replicate the key structural and functional characteristics of their in vivo counterparts. As organoid technology opens up new frontiers of research in biomedicine, there is an emerging need for innovative engineering approaches for the production, control, and analysis of organoids and their microenvironment. In this Review, we explore organ-on-a-chip technology as a platform to fulfill this need and examine how this technology may be leveraged to address major technical challenges in organoid research. We also discuss emerging opportunities and future obstacles for the development and application of organoid-on-a-chip technology.
                Bookmark

                Author and article information

                Contributors
                chencs@bu.edu
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                6 July 2020
                6 July 2020
                2020
                : 11
                : 3377
                Affiliations
                [1 ]ISNI 0000 0004 1936 7558, GRID grid.189504.1, Department of Biomedical Engineering, , Boston University, ; 610 Commonwealth Ave, Boston, MA 02215 USA
                [2 ]ISNI 000000041936754X, GRID grid.38142.3c, Wyss Institute for Biologically Inspired Engineering, , Harvard University, ; 3 Blackfan Circle, Boston, MA 02115 USA
                [3 ]ISNI 0000 0001 2297 6811, GRID grid.266102.1, Currently at Department of Cell and Tissue Biology, , University of California San Francisco, ; Box 0512, 513 Parnassus Avenue, San Francisco, CA 94143 USA
                [4 ]ISNI 0000 0001 1034 1720, GRID grid.410711.2, Currently at UNC/NCSU Joint Department of Biomedical Engineering, , University of North Carolina, ; 104 Manning Drive, Chapel Hill, NC 27599 USA
                [5 ]ISNI 000000041936754X, GRID grid.38142.3c, Massachusetts General Hospital Cancer Center, , Harvard Medical School, ; 149 13th Street, Charlestown, MA 02129 USA
                [6 ]Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Charlestown, MA 02129 USA
                Author information
                http://orcid.org/0000-0002-0752-649X
                http://orcid.org/0000-0003-2728-0746
                http://orcid.org/0000-0002-8898-9372
                Article
                17102
                10.1038/s41467-020-17102-x
                7338408
                32632100
                7d358a6c-d13e-43f1-bf69-8784c5a0e86d
                © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 24 October 2019
                : 5 June 2020
                Funding
                Funded by: FundRef https://doi.org/10.13039/100000002, U.S. Department of Health & Human Services | National Institutes of Health (NIH);
                Award ID: K99CA226366
                Award ID: R00CA226366
                Award ID: R01HL147585
                Award ID: R01EB00262
                Award ID: R01EB008396
                Award Recipient :
                Funded by: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
                Funded by: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
                Funded by: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
                Funded by: U.S. Department of Health & Human Services | National Institutes of Health (NIH)
                Funded by: National Science Foundation Center for Engineering MechanoBiology (CMMI15-48571) and the Biological Design Center at Boston University.
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                tissue engineering,breast cancer,cell adhesion,morphogen signalling,morphogenesis
                Uncategorized
                tissue engineering, breast cancer, cell adhesion, morphogen signalling, morphogenesis

                Comments

                Comment on this article